IL17A and Sepsis: Similarly, a mucosal-route S. aureus nanoemulsion vaccine in previous studies induced strong mucosal and systemic immune responses with high sIgA, IL-17A, and IFN-γ levels and displayed strong protective effects in sepsis and pneumonia models (60, 63).